The Filing Desk

Ceribell

CBLL · Nasdaq · Health Care · Financials, fiscal 2023 to 2025

CBLL · Last close · November 13, 2026
$26.14
Value Ceribell yourself

Ceribell's revenue rose 36.1% to $89 million in fiscal 2025. Its operating margin was −65.6%, down from −60.7% a year earlier. Free cash flow was −$42 million. The diluted share count rose 205.8%.

CeriBell, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 24, 2026 · 0001193125-26-067238 Updated
Revenue
$89M
36.1%
Operating margin
−65.6%
4.9 pts
Net income
−$53M
 
Free cash flow
−$42M
 
Return on equity
−30.8%
71.7 pts
Market cap
$1.0B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Ceribell does

Ceribell makes a portable system that records the brain's electrical activity, called an EEG, at the bedside of seriously ill hospital patients. Its main use is finding seizures, which in hospital patients often show no physical signs. The Ceribell System has a disposable headband or headcap, a pocket-sized battery-powered recorder, a web portal where neurologists view the signals and software that uses artificial intelligence to flag seizure activity.

Ceribell says conventional EEG machines need specialized technicians and a long setup, which delays diagnosis. It says its system can be put on by any healthcare worker after about one hour of training. Its customers are hospitals, and it says more than 600 hospitals had adopted it by the end of 2025.

It makes money in two recurring ways: it sells the single-use headbands and headcaps, and it charges hospitals a monthly subscription fee for the software, recorders and portal. Its seizure-detection software, called Clarity, got US Food and Drug Administration clearance in May 2023 for adults at risk of seizure. Ceribell says it competes with conventional EEG and other technologies, and it has a history of net losses.

Its biggest risks, as it describes them

  • A history of net losses, and a limited operating history with rapid growth that may strain its resources.
  • Relying on sales of one system, so hospitals not adopting it or losing confidence in it would hurt it.
  • Competition from established companies and from other technologies for detecting seizures.
  • Relying on manufacturing and supply chains abroad, and on trade policies and tariffs.
  • Hospitals and doctors not being reimbursed enough for tests that use its products.
From Ceribell's annual report on Form 10-K, filed February 24, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Ceribell lost money in fiscal 2025: a net loss of $53 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY23FY24FY25
Cash and short-term investments34194159
Debt incl. finance leases——20
Net debt (negative means net cash)——−140
Net debt to EBITDA———
Debt to equity——0.1x
Interest coverage−14.3x−19.9x−30.9x
Current ratio2.4x16.7x9.7x
Quick ratio2.1x16.2x9.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Ceribell's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Ceribell says to expect

  • Full year 2026: revenueCeribell is raising its revenue guidance for the full year 2026 to a range of $115 million to $117 million, representing growth of approximately 29% to 31% over the Company’s prior year revenue.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 3, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Ceribell reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25
Piotroski F-score——
Rule of 40−10.9%−10.6%
Altman Z''8.213.97
Accruals ratio−3.8%−6.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25
Net income is positiveFailFail
Cash from operations is positiveFailFail
Return on assets rose—Pass
Cash from operations exceeds net incomePassPass
Debt fell relative to assets——
Current ratio rosePassFail
Share count didn't riseFailFail
Gross margin rosePassPass
Revenue rose relative to assets—Fail
F-score——
Companies that report no gross profit are scored on the other eight.

Compare

Put Ceribell side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
CeribellFY2536.1%−65.6%−46.7%———
Delcath SystemsFY25129.1%0.8%24.6%2.8%−101.4x6Compare
IRADIMEDFY2514.4%31.2%20.5%———Compare
Kestra Medical TechnologiesFY2659.0%−141.6%−122.6%——4Compare
Butterfly NetworkFY2519.0%−88.5%−16.4%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

3 years of figures

Fiscal yearFY23FY24FY25
Income statement
Revenue456589
Revenue growth—44.7%36.1%
Gross profit385778
Research and development91419
Operating income−30−40−58
Net income−30−40−53
Diluted EPS (US$)−5.56−3.39−1.46
Diluted shares (millions)51236
Cash flow
Cash from operations−29−35−41
Capital expenditure111
Free cash flow−30−36−42
Dividends paid000
Share buybacks000
Acquisitions000
Stock-based compensation3512
Balance sheet at fiscal year end
Cash and short-term investments34194159
Debt incl. finance leases——20
Total assets59225196
Total liabilities243440
Shareholders' equity−112191155
Margins and ratios
Gross margin84.4%86.7%87.9%
Operating margin−66.4%−60.7%−65.6%
Net margin−65.2%−61.8%−60.0%
Free cash flow margin−66.7%−55.6%−46.7%
Rule of 40 (growth + FCF margin)—−10.9%−10.6%
Return on capital———
Return on equity—−102.5%−30.8%
Return on assets—−28.5%−25.4%
Net debt to EBITDA———
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Ceribell's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Ceribell.